다운로드 Oncology Nursing Drug Handbook - v3.5.13

카테고리 의료의 추천 애플리케이션 중 하나 인 Oncology Nursing Drug Handbook - v3.5.13을 (를) 다운로드하여 공유하세요.
또한 ALAT, iDentist Dental practice management, X-RAY WOW, NYP, MCQ Abubakr (ASU), Pacify로 다운로드 할 수있는 다른 애플리케이션도 있습니다. Oncology Nursing Drug Handbook - v3.5.13에 만족한다면.

Skyscape Medpresso Inc에서 출시 한 Oncology Nursing Drug Handbook - v3.5.13은 현재 사용 가능한 최고의 무료 및 최고의 휴대 전화 애플리케이션 중 하나입니다. 앱 스토어의 의료 카테고리에 있습니다.

Oncology Nursing Drug Handbook - v3.5.13의 최소 운영 체제는 Android 5.0+ 이상입니다. 아직 업데이트하지 않은 경우 휴대 전화를 업데이트해야합니다.

APKDroid에서는 Oncology Nursing Drug Handbook - v3.5.13 APK 무료 다운로드를 받게됩니다. 최신 버전은 3.5.13, 게시일은 2020-06-25이며 파일 크기는 8.4 MB입니다.Google Play 스토어 통계에 따르면 약 1000 회 다운로드가 있습니다. Android에 개별적으로 다운로드하거나 설치된 앱은 원하는 경우 업데이트 할 수 있습니다. 앱도 업데이트하세요. 최신 기능에 대한 액세스 권한을 부여하고 보안을 강화합니다. 그리고 앱의 안정성. 지금 즐기세요 !!!

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity